Page 2 - Allogene Allo News Today

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure... | May 3, 2023

Former Kite Pharma Executive Responsible for the Development and Commercial Launch of Two of the Most Successful Autologous CAR T Manufacturing Processes...

Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapySingle... | April 17, 2023

Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint...

Publication Reviews Investigation of a Chromosomal Rearrangement Observed in a Single Patient Receiving Gene-Edited Allogeneic CAR T Treatment for Large B Cell LymphomaCase Reveals Normal T Cell Biology Occurring in CAR T Cells, Including Notable Finding ...

13.12.2021 - ALPHA Trials Demonstrate Potential for AlloCAR T Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve PatientsAlloCAR T Therapy was Associated with Consistent and Manageable Safety with No DLTs or GvHD; Low Rates of ...